FEATURED

Revolution Medicines Surges 41% and Raises $750M to Commercialize Its Pancreatic Cancer Drug

Apr 15, 2026

•

10 min read

Revolution Medicines Surges 41% and Raises $750M to Commercialize Its Pancreatic Cancer Drug

RVMD hit an all-time high after nearly doubling survival in Phase 3. The company launched a $750M equity offering, plans to file under the CNPV program, and will present full data at ASCO 2026. Analyst targets raised to $147 to $165.

BioMed Nexus

THE LATEST

Apr 14, 2026

•

11 min read

A Pancreatic Cancer Drug Just Nearly Doubled Survival in a Phase 3 Trial

Revolution Medicines' daraxonrasib hit all endpoints in second-line metastatic pancreatic cancer. Median OS: 13.2 months vs. 6.7 months. Hazard ratio 0.40. Wall Street is calling it unprecedented. A first-line trial is already enrolling.

Apr 13, 2026

•

11 min read

FDA Rejects Replimune's Melanoma Drug Again, and the Company May Walk Away | The Week Ahead

RP1 got a second complete response letter on Friday. Replimune says development is no longer viable without accelerated approval. Biopharma raised $22.8B in Q1. Plus a full look at the week ahead.

Apr 10, 2026

•

12 min read

PhRMA's Longest-Serving CEO Is Stepping Down • FDA Proposes a Faster Path to Phase 1

Steve Ubl exits after a decade navigating drug pricing wars and the pandemic. The FDA wants an expedited IND pathway to speed Phase 1 trials. Plus: the week in review.

Sanofi's Dupixent Successor Hits in Asthma, Misses in Eczema • AbbVie Lists Humira on TrumpRx at 86% Off

Lunsekimig met primary endpoints in asthma and nasal polyps but missed in atopic dermatitis. AbbVie's 86% Humira discount signals how pharma is responding to Section 232 tariffs. Foundayo rollout continues.

Gilead Makes Its Third Acquisition in 6 Weeks • Neurocrine Pays $2.9B for Prader-Willi Drug

Gilead pays up to $5B for ADC specialist Tubulis. That's $15B in 3 deals since late February. Neurocrine enters rare metabolic disease with Soleno's Vykat XR. The M&A machine keeps running.

Lilly's Oral GLP-1 Foundayo Is Approved and Shipping • Anthropic Pays $400M for a Biotech AI Team

The FDA approved orforglipron on April 1 under the CNPV program. It's already shipping through LillyDirect at $149/month. Anthropic acquired a 10-person biotech AI startup. Takeda dumps Denali. The global pipeline contracts for the first time in 30 years.

Trump Imposes 100% Tariffs on Patented Pharmaceuticals

The Section 232 order is the most significant trade action to hit pharma in decades. Generics and biosimilars are exempt. Companies with MFN pricing deals pay zero. A separate investigation into medical devices is active. Orforglipron in 4 days.

Q1 Ends with $46.8B in M&A and a 7% XBI Surge • Immunovant TED Trial Misses

Biopharma spent nearly $47B on 19 deals in Q1. The XBI surged 7% on the last day of the quarter. Immunovant's batoclimab missed in both Phase 3 TED studies. Orforglipron in 7 days.

Novo Launches Wegovy Subscriptions, Cuts 400 Manufacturing Jobs, and Medtronic Expands Its Surgical Robot

Novo's new pricing model signals where obesity is headed. 400 jobs gone at the ex-Catalent site. Medtronic's Stealth Axis cleared for cranial and ENT. Orforglipron in 8 days.

$13.4B in M&A Drops in a Single Day • Lilly Enters Sleep Medicine

Lilly pays $7.8B for Centessa's narcolepsy pipeline. Biogen pays $5.6B for Apellis at a 140% premium. And orforglipron is 9 days away.

Lilly’s $2.75B AI Deal Resets Drug Discovery

Largest AI drug deal ever. Takeda cuts 634 jobs. White House circulates drug pricing legislation.

SUBSCRIBE TO OUR NEWSLETTER

Stay on the Cutting Edge of Biotech, MedTech, and Pharma.